ON DEMAND: Bispecifics vs. CAR-T in myeloma – questions, controversies and practicalities

6 Nov 2023

Watch again as an expert panel discusses the pros and cons of these revolutionary therapies and takes a case based approach to explore their place in Australian myeloma management.

Hosted by Professor Simon Harrison
Haematologist and Clinician Scientist, Sir Peter MacCallum Department of Oncology, University of Melbourne; Director of the Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre; Chair of the Myeloma Scientific and Advisory Group (MSAG), Myeloma Australia.

Special guest: Associate Professor Adam Cohen
Hospital of the University of Pennsylvania (Haemato-Oncology); Director, Myeloma Immunotherapy, University of Pennsylvania; Member, Abramson Cancer Center; Co-Director, Amyloidosis Program, University of Pennsylvania.

Sam Van Der Linde. Centre of Excellence for Cellular Immunotherapy and Clinical Haematology, Peter MacCallum Cancer Centre.

Dr Jay Hocking. Clinical Haematologist, Myeloma Lead, ONJ Centre, Austin Hospital; Epworth Eastern and Box Hill Hospitals.

Thank you to our sponsors

For more information, please contact [email protected].

This event was supported by unrestricted educational grants. It was created independently by the limbic in collaboration with MSAG and the participants. All views expressed are those of the participants only.

Already a member?

Login to keep reading.

Email me a login link